EUVIMEDEUVIMED entdecken
Crossref

Functionalized Red Blood Cell Membrane Nanoplatform for Paclitaxel and Artesunate Induces Ferroptosis and Immunogenic Cell Death against Triple-Negative Breast Cancer

Kaiming Li iD, Xiaole Zhu, Haisi Wu, Jiang Li, Fan Wu, Jianjun Zhang, Jiayi Cai, Zheng Shi, Xingguo Zhang, Shengyang Xie, Rui Xie iD

ACS Applied Materials & Interfaces · 2026

DOI: 10.1021/acsami.6c13085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Kaiming Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hang…. Hauptthemen laut MEDLINE: Paclitaxel, Artesunate, Triple Negative Breast Neoplasms, Ferroptosis. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Research Project of Zhejiang Chinese Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) tends to exhibit extremely large rates of tumor recurrence and mortality owing to the absence on effective therapeutic targets. Paclitaxel is the chemotherapeutic drug of choice, but the clinical efficacy in TNBC is limited. In the present study, we developed a folic acid (FA)-modified red blood cell membrane biomimetic drug delivery system encapsulating both paclitaxel and artesunate (PA@LRM-FA) against TNBC, aimed at enhancing ferroptosis and promoting immunogenic cell death to improve paclitaxel efficacy. The morphology, particle size, zeta potential, particle stability, paclitaxel and artesunate loading capacity, and paclitaxel and artesunate encapsulation efficiency of the formulations were studied. Through a cellular assay, we discovered that PA@LRM-FA inhibited the 4T1 cell proliferation, induced ROS accumulation, and promoted ferroptosis and immunogenic cell death. In tumor-bearing mice, PA@LRM-FA effectively targeted tumor tissues for the delivery of paclitaxel and artesunate and significantly induced ferroptosis, promoting immunogenic cell death and active immune cells in 4T1 tumors, resulting in a marked inhibition of tumor growth. Taken together, this work demonstrated a feasible therapeutic approach to inhibit TNBC by enhancing tumor ferroptosis and immunogenic cell death through PA@LRM-FA delivery of paclitaxel and artesunate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelArtesunateTriple Negative Breast NeoplasmsFerroptosisImmunogenic Cell DeathErythrocyte MembraneNanoparticlesAnimalsFemaleMiceHumansCell Line, TumorMice, Inbred BALB CCell ProliferationFolic Acid

Stichwörter der Autor:innen

artesunateferroptosisimmunogenic cell deathpaclitaxelred blood cell membrane delivery systemtriple-negative breast cancer

Substanzen

PaclitaxelArtesunateFolic Acid

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou310000, China.
  • Department of Emergency, The First Affiliated Hospital of Nanjing Medical University, Nanjing210029, China.
  • State Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen518055, China.
  • The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou310000, China.

ORCID-Profile: Kaiming Li, Rui Xie

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • Research Project of Zhejiang Chinese Medical University
  • First Affiliated Hospital of Nanjing Medical University
  • Medical and Health Science Program of Zhejiang Province
  • ?Renhe Youbo? talent plan of Zhejiang Provincial Hospital of Traditional Chinese Medicine
  • Hainan Hongji Medical Development Foundation

Zitieren

APA

Li, K., Zhu, X., Wu, H., Li, J., Wu, F., Zhang, J., Cai, J., Shi, Z., Zhang, X., Xie, S., & Xie, R. (2026). Functionalized Red Blood Cell Membrane Nanoplatform for Paclitaxel and Artesunate Induces Ferroptosis and Immunogenic Cell Death against Triple-Negative Breast Cancer. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c13085

Vancouver

Li K, Zhu X, Wu H, Li J, Wu F, Zhang J, et al. Functionalized Red Blood Cell Membrane Nanoplatform for Paclitaxel and Artesunate Induces Ferroptosis and Immunogenic Cell Death against Triple-Negative Breast Cancer. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c13085

BibTeX
@article{Li2026,
  author = {Li, Kaiming and Zhu, Xiaole and Wu, Haisi and Li, Jiang and Wu, Fan and Zhang, Jianjun and Cai, Jiayi and Shi, Zheng and Zhang, Xingguo and Xie, Shengyang and Xie, Rui},
  title = {Functionalized Red Blood Cell Membrane Nanoplatform for Paclitaxel and Artesunate Induces Ferroptosis and Immunogenic Cell Death against Triple-Negative Breast Cancer},
  journal = {ACS Applied Materials & Interfaces},
  year = {2026},
  doi = {10.1021/acsami.6c13085}
}
Kostenlos starten →